Is alpha-b crystallin an independent marker for prognosis in lung cancer?

Heart Lung and Circulation

Volumn 22, Issue 9, 2013, Pages 759-766

  Campbell Lloyd, Andrew J M ^a   Mundy, Julie ^a   Deva, Rajeev ^a   Lampe, Guy ^a   Hawley, Carmel ^a,c   Boyle, Glen ^b   Griffin, Rayleene ^a   Thompson, Charles ^c   Shah, Pallav ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Lung cancer; Markers; Outcomes

Indexed keywords

ALPHA B CRYSTALLIN; ALPHA B CRYSTALLIN ANTIBODY; ALPHA CRYSTALLIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ALPHA B CRYSTALLIN GENE; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CLINICAL ARTICLE; EXPLORATORY RESEARCH; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; ONCOGENE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL;

LUNG CANCER; MARKERS; OUTCOMES;

ADENOCARCINOMA; AGED; ALPHA-CRYSTALLIN B CHAIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84884352500     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2013.01.014     Document Type: Article

References (29)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. West H., Lilenbaum R., Harpole D., Wozniak A., Sequist L. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol 2009, 4:s1029-s1039.
3. Sienel W., Dango S., Ehrhardt P., Eggeling S., Kirschbaum A., Passlick B. The future in diagnosis and staging of lung cancer. Molecular techniques. Respiration 2006, 73:575-580.
4. Blanchon F., Grivaux M., Asselain B., Lebas F.X., Orlando J.P., Piquet J., et al. 4-Year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006, 7:829-836.
5. Sculier J.P., Chansky K., Crowley J.J., Van Meerbeeck J., Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol 2008, 3:457-466.
6. Parcellier A., Schmitt E., Brunet M., Hammann A., Solary E., Garrido C. Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signal 2005, 7:404-413.
7. Kamradt M.C., Chen F., Cryns V.L. The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 2001, 276:16059-16063.
8. Kamradt M.C., Chen F., Sam S., Cryns V.L. The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J Biol Chem 2002, 277:38731-38736.
9. Kamradt M.C., Lu M., Werner M.E., Kwan T., Chen F., Strohecker A., et al. The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 2005, 280:11059-11066.
10. Liu S., Li J., Tao Y., Xiao X. Small heat shock protein alphaB-crystallin binds to p53 to sequester its translocation to mitochondria during hydrogen peroxide-induced apoptosis. Biochem Biophys Res Commun 2007, 354:109-114.
11. Li D.W., Liu J.P., Mao Y.W., Xiang H., Wang J., Ma W.Y., et al. Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation. Mol Biol Cell 2005, 16:4437-4453.
12. Moyano J.V., Evans J.R., Chen F., Lu M., Werner M.E., Yehiely F., et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006, 116:261-270.
13. Gruvberger-Saal S.K., Parsons R. Is the small heat shock protein alphaB-crystallin an oncogene?. J Clin Invest 2006, 116:30-32.
14. Sebolt-Leopold J.S. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 2008, 14:3651-3656.
15. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24-40.
16. Dimberg A., Rylova S., Dieterich L.C., Olsson A.K., Schiller P., Wikner C., et al. AlphaB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. Blood 2008, 111:2015-2023.
17. Lin D.I., Barbash O., Kumar K.G., Weber J.D., Harper J.W., Klein-Szanto A.J., et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell 2006, 24:355-366.
18. Iwaki T., Kume-Iwaki A., Goldman J.E. Cellular distribution of alpha B-crystallin in non-lenticular tissues. J Histochem Cytochem 1990, 38:31-39.
19. Klemenz R., Andres A.C., Frohli E., Schafer R., Aoyama A. Expression of the murine small heat shock proteins hsp 25 and alpha B crystallin in the absence of stress. J Cell Biol 1993, 120:639-645.
20. Pinder S.E., Balsitis M., Ellis I.O., Landon M., Mayer R.J., Lowe J. The expression of alpha B-crystallin in epithelial tumours: a useful tumour marker?. J Pathol 1994, 174:209-215.
21. Chelouche-Lev D., Kluger H.M., Berger A.J., Rimm D.L., Price J.E. AlphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 2004, 100:2543-2548.
22. Mineva I., Gartner W., Hauser P., Kainz A., Loffler M., Wolf G., et al. Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing. Cell Stress Chaperones 2005, 10:171-184.
23. Lung H.L., Lo C.C., Wong C.C., Cheung A.K., Cheong K.F., Wong N., et al. Identification of tumor suppressive activity by irradiation microcell-mediated chromosome transfer and involvement of alpha B-crystallin in nasopharyngeal carcinoma. Int J Cancer 2008, 122:1288-1296.
24. Boslooper K., King-Yin Lam A., Gao J., Weinstein S., Johnson N. The clinicopathological roles of alpha-B-crystallin and p53 expression in patients with head and neck squamous cell carcinoma. Pathology 2008, 40:500-504.
25. Chin D., Boyle G.M., Williams R.M., Ferguson K., Pandeya N., Pedley J., et al. Alpha B-crystallin, a new independent marker for poor prognosis in head and neck cancer. Laryngoscope 2005, 115:1239-1242.
26. Tang Q., Liu Y.F., Zhu X.J., Li Y.H., Zhu J., Zhang J.P., et al. Expression and prognostic significance of the alpha B-crystallin gene in human hepatocellular carcinoma. Hum Pathol 2009, 40:300-305.
27. Cherneva R., Petrov D., Georgiev O., Slavova Y., Toncheva D., Stamenova M., et al. Expression profile of the small heat-shock protein alpha-B-crystallin in operated-on non-small-cell lung cancer patients: clinical implication. Eur J Cardiothorac Surg 2010, 37:44-50.
28. Mino N., Takenaka K., Sonobe M., Miyahara R., Yanagihara K., Otake Y., et al. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol 2007, 95:250-257.
29. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006, 355:570-580.